Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy-Reference-Cited by-同舟云学术

Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy

Published:2023-12 Issue:6 Volume:8 Page:102066
ISSN:2059-7029
Container-title:ESMO Open
language:en
Short-container-title:ESMO Open

Author:

Abed A.,Beasley A.B.,Reid A.L.,Law N.,Calapre L.,Millward M.,Lo J.,Gray E.S.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference33 articles.

1. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial;Mok;Lancet,2019

2. Pembrolizumab plus chemotherapy for squamous non–small-cell lung cancer;Paz-Ares;N Engl J Med,2018

3. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy;Havel;Nat Rev Cancer,2019

4. Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer;Lopez de Rodas;J Immunother Cancer,2022

5. Prognostic value of HLA-I homozygosity in patients with non-small cell lung cancer treated with single agent immunotherapy;Abed;J Immunother Cancer,2020

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tissue and Peripheral T-cell Repertoire Predicts Immunotherapy Response and Progression-Free Survival in NSCLC Patients;2024-08-02

2. Exploring the potential of the TCR repertoire as a tumor biomarker (Review);Oncology Letters;2024-06-28